文献速递淋巴瘤造血干细胞移植与细胞治疗

接受CD19靶向CAR-T细胞治疗的侵袭性淋巴瘤患者中CHIP的患病率及变异

Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment.
PubMed 文献 · Blood Adv · 2022-01-01

该研究对32例复发/难治性B细胞非霍奇金淋巴瘤患者在CAR-T治疗前后进行靶向深度测序评估CHIP,发现治疗前CHIP患病率为34%(11/32),CHIP患者总生存改善(未达到 vs 265天,P=.003),但CRS/ICANS发生率和严重程度无显著差异。

要点

  • CAR-T治疗前CHIP患病率为34%(11/32),CHIP进展在后期病程中常见。
  • CHIP患者总生存改善(未达到 vs 265天,P=.003),但缓解率与无CHIP者相当。
  • CHIP与CRS/ICANS发生率及严重程度、托珠单抗和糖皮质激素使用无显著差异。

核心结论

  • CHIP在接受CD19靶向CAR-T细胞治疗的患者中常见,且与较差结局无关。

研究设计与样本

  • 研究纳入32例复发/难治性B细胞非霍奇金淋巴瘤患者,在CAR-T细胞治疗前后采用靶向深度测序方法评估CHIP。

主要发现

  • CAR-T治疗前CHIP见于11/32例患者(34%)。
  • CHIP进展在后期病程中常见。
  • CHIP患者缓解率与无CHIP者相当,但总生存改善(未达到 vs 265天,P=.003)。
  • CHIP与无CHIP患者在CRS/ICANS发生率和严重程度、托珠单抗和糖皮质激素使用、炎症旁临床标志物(铁蛋白除外)及造血恢复动态方面无显著差异。

关键数值与推荐

  • CHIP患病率:34%(11/32)。
  • 总生存:CHIP患者未达到 vs 无CHIP患者265天(P=.003)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inflammation plays an important role in chimeric antigen receptor (CAR) T-cell therapy, especially in the pathophysiology of cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Clonal hematopoiesis of indetermined potential (CHIP) has also been associated with chronic inflammation. The relevance of CHIP in the context of CAR T-cell treatment is widely unknown. We evaluated the prevalence of CHIP, using a targeted deep sequencing approach, in a cohort of patients with relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma before and after CAR T-cell treatment. The aim was to define the prevalence and variation of CHIP over time and to assess the influence on clinical inflammation syndromes (CRS/ICANS), cytopenia, and outcome. Overall, 32 patients were included. CHIP was found in 11 of 32 patients (34%) before CAR T-cell therapy. CHIP progression was commonly detected in the later course. Patients with CHIP showed a comparable response rate to CAR T-cell treatment but had an improved overall survival (not reached vs 265 days, P = .003). No significant difference was observed in terms of the occurrence and severity of CRS/ICANS, therapeutic use of tocilizumab and glucocorticosteroids, paraclinical markers of inflammation (with the exception of ferritin), or dynamics of hematopoietic recovery. CHIP is commonly observed in patients undergoing CD19-directed CAR T-cell therapy and is not associated with an inferior outcome.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Teipel R, Kroschinsky F, Kramer M, et al. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Adv. 2022. PMID: 35008107. doi:10.1182/bloodadvances.2021005747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。